RxDoctor Payments Data

Eric Janis, MD

Cardiovascular Disease · Smithfield, NCNPI 1780682484

Payments from drug & device makers

$239,759in general payments, 2019–2025

Across 106 payments — averaging $2261.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Contego Medical, Inc$237K
  • Boston Scientific$832
  • Abbott$560
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$414
  • Osprey Medical Inc$263
  • Irhythm Technologies, Inc.$156
  • plus $781 from 15 others

What the payments were for

  • Food & beverage$3,005100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$239,759 in reported general payments places this provider in the 90th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$307,575
Medicare patients
1,078
Services billed
5,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,029$793,761
Repatha SureclickEvolocumab168$211,398
EntrestoSacubitril/Valsartan215$186,959
XareltoRivaroxaban176$141,594
Praluent PenAlirocumab32$35,009
JardianceEmpagliflozin41$32,474
BrilintaTicagrelor52$30,728
Propafenone Hcl ErPropafenone Hcl156$26,645
Rosuvastatin Calcium1,218$13,611
VascepaIcosapent Ethyl32$11,601
Propafenone Hcl387$11,274
Metoprolol Succinate910$9,489
Ezetimibe556$7,433
Dofetilide22$7,220
ClopidogrelClopidogrel Bisulfate661$6,517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$793,7611,029 claims
NovartisEntresto$128$186,959215 claims
Johnson & JohnsonXarelto$47$141,594176 claims
Boehringer IngelheimJardiance$36$32,47441 claims
AstraZenecaBrilinta$85$30,72852 claims
Sanofi-aventis U.S. LLCPlavix$15$2,41811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Smithfield

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →